Ribavirin and Zemplar drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ribavirin (ribavirin) and Zemplar (paricalcitol). Common drug interactions include fatigue among females and anaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Ribavirin and Zemplar. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Ribavirin?

Ribavirin has active ingredients of ribavirin. It is often used in hepatitis c. eHealthMe is studying from 78,532 Ribavirin users. Check the latest studies of Ribavirin.

What is Zemplar?

Zemplar has active ingredients of paricalcitol. It is often used in kidney disease. eHealthMe is studying from 15,494 Zemplar users. Check the latest studies of Zemplar.



On Aug, 03, 2026

16 people who take Ribavirin and Zemplar together, and have interactions are studied.

Ribavirin and Zemplar drug interactions.

What are the common drug interactions of Ribavirin and Zemplar, by gender? *:

female:

  1. Fatigue (feeling of tiredness)
  2. Haemoglobin decreased
  3. Headache (pain in head)
  4. Nausea (feeling of having an urge to vomit)
  5. Oropharyngeal pain
  6. Pain
  7. Pyrexia (fever)
  8. Rhinorrhoea (watery mucus discharge from the nose)
  9. Vomiting
  10. Anaemia (lack of blood)

male:

  1. Anaemia (lack of blood)
  2. Dizziness
  3. White blood cell count decreased
  4. Abscess oral (abscess in the mouth)
  5. Anaemia macrocytic (a macrocytic class of anaemia)
  6. Anxiety
  7. Aortic dilatation
  8. Arteriovenous fistula
  9. Arthralgia (joint pain)
  10. Asthenia (weakness)

What are the common drug interactions of Ribavirin and Zemplar, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Anaemia (lack of blood)
  2. Folliculitis (infection of hair root)
  3. Hyperlipidaemia (presence of excess lipids in the blood)
  4. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  5. Meniscus lesion (lesion of a crescent-shaped piece of cartilage between the femur and the tibia)
  6. Pneumonia
  7. Retroperitoneal haemorrhage (bleeding between the peritoneum and the posterior abdominal wall)
  8. Staphylococcal infection (an infection with staphylococcus bacteria)
  9. Weight decreased
  10. White blood cell count decreased

20-29:

  1. Muscular weakness (muscle weakness)
  2. Nephrosclerosis (hardening of the kidney due to renovascular disease)
  3. Nephrotic syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema)
  4. Neuropathy peripheral (surface nerve damage)
  5. Neutropenia (an abnormally low number of neutrophils)
  6. Oedema (fluid collection in tissue)
  7. Oedema peripheral (superficial swelling)
  8. Oral pain
  9. Oropharyngeal pain
  10. Osteitis (a general term for inflammation of bone)

30-39:

  1. Headache (pain in head)
  2. Nausea (feeling of having an urge to vomit)
  3. Oropharyngeal pain
  4. Pain
  5. Pyrexia (fever)
  6. Rhinorrhoea (watery mucus discharge from the nose)
  7. Vomiting
  8. Anaemia (lack of blood)
  9. Cardiac murmur (an heart sound in valve abnormality)
  10. Dermal cyst

40-49:

  1. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)

50-59:

n/a

60+:

  1. Anaemia (lack of blood)
  2. Dizziness
  3. Dyspnoea exertional (breathlessness or shortness of breath)
  4. Fatigue (feeling of tiredness)
  5. Presyncope

What are the existing conditions these people have? *

  1. Chronic Renal Failure (kidney failure): 7 people, 43.75%
  2. Headache (pain in head): 2 people, 12.50%
  3. Anaemia (lack of blood): 2 people, 12.50%
  4. Weakness: 1 person, 6.25%
  5. Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 6.25%
  6. Pain: 1 person, 6.25%
  7. Nervous System Disorder (a general class of medical conditions affecting the nervous system): 1 person, 6.25%
  8. Musculoskeletal Discomfort (discomfort in the body's muscles, joints, tendons, ligaments and nerves): 1 person, 6.25%
  9. Multiple Myeloma (cancer of the plasma cells): 1 person, 6.25%
  10. Localised Oedema (fluid retention in a particular part of the body): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Ribavirin and Zemplar?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ribavirin and Zemplar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ribavirin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Zemplar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ribavirin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Zemplar and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on ribavirin and paricalcitol (the active ingredients of Ribavirin and Zemplar, respectively), and Ribavirin and Zemplar (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: